Renal cell carcinoma

Objectif pédagogique: To assess the recurrence risk after nephrectomy and appropriately select patients who are at high risk of renal cell carcinoma (RCC) recurrence and may benefit from adjuvant treatment.

Spécialité: Urology, Medical oncology, Clinical oncology

Public cible: Specialists (CME: basic, intermediate), Residents (senior)

Dernière mise à jour: January 2025

Contexte:

Regulatory approval status of drugs mentioned in this CME course, restricted to the adjuvant treatment setting (status 22 January 2025)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.